EP1248607A4 - Urotensin-ii rezeptorantagonisten - Google Patents

Urotensin-ii rezeptorantagonisten

Info

Publication number
EP1248607A4
EP1248607A4 EP00988185A EP00988185A EP1248607A4 EP 1248607 A4 EP1248607 A4 EP 1248607A4 EP 00988185 A EP00988185 A EP 00988185A EP 00988185 A EP00988185 A EP 00988185A EP 1248607 A4 EP1248607 A4 EP 1248607A4
Authority
EP
European Patent Office
Prior art keywords
urotensin
receptor antagonists
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00988185A
Other languages
English (en)
French (fr)
Other versions
EP1248607A1 (de
Inventor
Dashyant Dhanak
Steven D Knight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1248607A1 publication Critical patent/EP1248607A1/de
Publication of EP1248607A4 publication Critical patent/EP1248607A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
EP00988185A 1999-12-21 2000-12-19 Urotensin-ii rezeptorantagonisten Withdrawn EP1248607A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17280799P 1999-12-21 1999-12-21
US172807P 1999-12-21
PCT/US2000/034574 WO2001045694A1 (en) 1999-12-21 2000-12-19 Urotensin-ii receptor antagonists

Publications (2)

Publication Number Publication Date
EP1248607A1 EP1248607A1 (de) 2002-10-16
EP1248607A4 true EP1248607A4 (de) 2004-10-06

Family

ID=22629329

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00988185A Withdrawn EP1248607A4 (de) 1999-12-21 2000-12-19 Urotensin-ii rezeptorantagonisten

Country Status (5)

Country Link
EP (1) EP1248607A4 (de)
JP (1) JP2003518057A (de)
AU (1) AU2441801A (de)
CA (1) CA2394603A1 (de)
WO (1) WO2001045694A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310490A4 (de) * 2000-07-04 2004-03-17 Takeda Chemical Industries Ltd Gpr14-antagonisten
US20030207863A1 (en) * 2000-08-25 2003-11-06 Hiroaki Fukumoto Preventives and remedies for central nervous system diseases
NZ527276A (en) 2001-03-27 2004-11-26 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists
US20040142923A1 (en) * 2001-03-29 2004-07-22 Dashyant Dhanak Pyrrolidine sulfonamides
EP1399137A4 (de) * 2001-05-07 2005-12-14 Smithkline Beecham Corp Sulfonamide
EP1385830A4 (de) * 2001-05-07 2005-08-17 Smithkline Beecham Corp Sulfonamide
WO2002089793A1 (en) * 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
WO2002089740A2 (en) * 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
IL162851A0 (en) 2001-12-04 2005-11-20 Actelion Pharmaceuticals Ltd 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
US20060004010A1 (en) * 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
EP1549639B1 (de) 2002-10-07 2006-05-24 Glaxo Group Limited Sulfonamidderivate als antipsychotische mittel
EP1670470B1 (de) 2003-09-26 2009-04-08 Actelion Pharmaceuticals Ltd. Pyridin-derivate und ihre verwendung als urotensin ii antagonisten
AR051213A1 (es) 2004-10-12 2006-12-27 Actelion Pharmaceuticals Ltd 1-(2-(4-bencil-4-hidroxi-piperidin-1-il)-etil)-3-(2-metil-quinolin-4-il)-urea como una sal sulfato cristalina
EP1976495A2 (de) * 2006-01-06 2008-10-08 Aarhus Universitet Auf den serotonin-transporter wirkende verbindungen
KR101546562B1 (ko) * 2008-10-22 2015-08-25 어큐셀라 인코포레이티드 안과 질환 및 장애 치료용 화합물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430757A1 (de) * 1994-08-30 1996-03-07 Boehringer Mannheim Gmbh Neue 4-Aminopyridazine, Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
R. M. JONES, P. D. BOATMAN, G. SEMPLE, Y-J SHIN, S. Y. TAMURA: "Clinically validated peptides as templates for de novo peptidomimetic drug design at G-protein-coupled receptors", CURRENT OPINION IN PHARMACOLOGY, vol. 3, 2003, pages 530 - 543, XP002290594 *
S. A. DOUGLAS, D. DHANAK, D. G. JOHNS: "From 'grills to pills': urotensin-II as a regulator of mammalian cardiorenal function", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 25, no. 2, 2004, pages 76 - 85, XP002290593 *
See also references of WO0145694A1 *

Also Published As

Publication number Publication date
CA2394603A1 (en) 2001-06-28
EP1248607A1 (de) 2002-10-16
WO2001045694A1 (en) 2001-06-28
AU2441801A (en) 2001-07-03
JP2003518057A (ja) 2003-06-03

Similar Documents

Publication Publication Date Title
EP1229910A4 (de) Integrinrezeptorantagonisten
EP1194151A4 (de) Antagonisten der integrin rezeptoren
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
IL146112A0 (en) Bradykinin receptor antagonists
EP1248607A4 (de) Urotensin-ii rezeptorantagonisten
IL145761A0 (en) Il-8 receptor antagonists
EP1359915A4 (de) Urotensin-ii-rezeptor-antagonisten
IL146151A0 (en) Human-g-protein receptor
IL148043A0 (en) Novel integrin receptor antagonists
EP1185265A4 (de) Il-8 rezeptorantagonisten
AU2002226048A1 (en) Urotensin-ii receptor antagonists
EP1351687A4 (de) Urotensin-ii-rezeptor-antagonisten
EP1180028A4 (de) Il-8 rezeptorantagonist
IL146146A0 (en) Integrin receptor antagonists
GC0000203A (en) Vitronectin receptor antagonists
HUP0201302A3 (en) Il-8 receptor antagonists
EP1194143A4 (de) Il-8 rezeptor-antagonisten
GB0026327D0 (en) Thrombin receptor antagonists
HK1044475A1 (zh) Il-8受體拮抗劑
HUP0202019A3 (en) Il-8 receptor antagonists
HUP0202004A2 (en) Il-8 receptor antagonists
AU2512800A (en) Alpha1-adrenergic receptor antagonists
GB9811283D0 (en) Vironectin receptor antagonists
EP1237548A4 (de) Il-8 rezeptor antagonisten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020620

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/38 B

Ipc: 7C 07D 217/12 B

Ipc: 7C 07D 285/16 B

Ipc: 7C 07D 213/89 B

Ipc: 7C 07D 213/70 B

Ipc: 7A 61K 31/44 B

Ipc: 7A 61K 31/335 B

Ipc: 7C 07D 307/68 B

Ipc: 7C 07D 271/12 B

Ipc: 7C 07D 333/24 B

Ipc: 7C 07C 311/29 B

Ipc: 7C 07D 333/62 B

Ipc: 7C 07C 311/21 B

Ipc: 7C 07C 303/38 B

Ipc: 7C 07C 311/44 B

Ipc: 7A 61K 31/18 A

Ipc: 7A 61K 31/425 B

Ipc: 7C 07D 319/18 B

A4 Supplementary search report drawn up and despatched

Effective date: 20040820

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060929